Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19

Raymund R. Razonable; Ravindra Ganesh; Dennis M. Bierle

doi:10.1016/j.mayocp.2021.11.017

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19

Raymund R. Razonable, Ravindra Ganesh, Dennis M. Bierle

Infectious Diseases

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	26-30
Number of pages	5
Journal	Mayo Clinic proceedings
Volume	97
Issue number	1
DOIs	https://doi.org/10.1016/j.mayocp.2021.11.017
State	Published - Jan 2022

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/j.mayocp.2021.11.017

Cite this

@article{d26b9cd6f9c8468783acf92a833cd279,

title = "Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19",

author = "Razonable, {Raymund R.} and Ravindra Ganesh and Bierle, {Dennis M.}",

note = "Funding Information: Potential Competing Interests: Dr Razonable has received research grants from Regeneron, Roche, and Gilead. The other authors report no competing interests. Funding Information: Grant Support: The work was supported by Mayo Clinic Research Funds (R.R.R.). ",

year = "2022",

month = jan,

doi = "10.1016/j.mayocp.2021.11.017",

language = "English (US)",

volume = "97",

pages = "26--30",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "1",

}

TY - JOUR

T1 - Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19

AU - Razonable, Raymund R.

AU - Ganesh, Ravindra

AU - Bierle, Dennis M.

N1 - Funding Information: Potential Competing Interests: Dr Razonable has received research grants from Regeneron, Roche, and Gilead. The other authors report no competing interests. Funding Information: Grant Support: The work was supported by Mayo Clinic Research Funds (R.R.R.).

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85121610837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121610837&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2021.11.017

DO - 10.1016/j.mayocp.2021.11.017

M3 - Short survey

C2 - 34996562

AN - SCOPUS:85121610837

SN - 0025-6196

VL - 97

SP - 26

EP - 30

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 1

ER -

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this